Silverback Therapeutics nabs $78.5m Series B
Seattle-based Silverback Therapeutics, a biopharmaceutical company, has secured $78.5 million in Series B financing.
Seattle-based Silverback Therapeutics, a biopharmaceutical company, has secured $78.5 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination
